Eoflow (294090) Q2 2026 earnings summary

Executive summary

• Specializes in wearable medical devices, focusing on insulin patch pumps and automated insulin delivery systems for diabetes management.

• Faced significant operational and financial challenges due to ongoing litigation with Insulet Corporation, impacting sales and market access.

• Major shareholder changed to Citadel Multi-Asset Master Fund Ltd. after a third-party allotment in late 2025.

Financial highlights

• 1H 2026 consolidated revenue was KRW 222 million, down sharply from KRW 1,897 million in 1H 2025.

• Operating loss for 1H 2026 was KRW -5,760 million; net loss was KRW -14,037 million.

• Total assets at June 30, 2026: KRW 31,011 million; total liabilities: KRW 78,320 million; negative equity of KRW -47,309 million.

• Cash and cash equivalents at period end: KRW 3,051 million.

• No dividends paid due to accumulated losses.

Outlook and guidance

• Plans to resume global sales and expand user base as litigation-related uncertainties are resolved.

• Focus on FDA approval and North American market entry, with ongoing product development and regulatory preparations.

• Strategic emphasis on partnerships and diversified funding to reduce reliance on a single investor.